Key Takeaways Appendix cancers are rare but potentially on the riseResearch suggests that in many cases, patients don't need ...

Most patients with localized appendix cancer may be able to safely avoid chemotherapy after surgery, according to a new study ...

HOUSTON, SEPTEMBER 9, 2026 ― Most patients with localized appendix cancer may be able to safely avoid chemotherapy after surgery, according to a ...

Add Yahoo as a preferred source to see more of our stories on Google. It’s the one organ we’ve been told is basically useless, and now it might actually be harboring a stealthy health risk. So ...

Once considered an outlier in gastrointestinal oncology, appendix cancer is now at the forefront of precision medicine, driven by genomic insights, personalized therapies, and a surge in scientific ...

Innovative application of an existing drug offers promising alternative treatment to traditional chemotherapy for patients with appendix cancer. Researchers at University of California San Diego ...

PITTSBURGH (KDKA) — Pittsburgh has become one of the top places in the world for the treatment of appendix cancer – a rare cancer affecting one in a million people. Many of them were told they had ...

A swollen abdomen, unexplained weight changes, or persistent stomach discomfort are usually caused by common digestive problems such as constipation, indigestion, or infections. However, when these ...

Targeting mutant KRAS may offer a promising new treatment option for appendix cancer, according to research from The University of Texas MD Anderson Cancer Center published in the Journal of ...

TAMPA, Fla. — More people in their 30s and 40s are being diagnosed with appendix cancer than ever before. A new study published in the Annals of Internal Medicine shows that appendix cancer rates have ...

Brian Johnson was told his type of cancer was so rare, doctors in his home state of Oregon only see about three cases per year. As if an appendiceal cancer diagnosis for a middle-aged father wasn’t ...

KRAS is the most common genetic mutation in appendix cancer, occurring in approximately 80% of mucinous tumors, the most common subtype KRAS-targeted therapies demonstrate robust activity in early ...